Dr. Reddy’s Laboratories (NYSE:RDY) today announced that the U.S. Food
and Drug Administration has granted approval of the Company’s
Abbreviated New Drug Application (ANDA) for Omeprazole Mg OTC. Shipment
of the product will be phased over the remainder of the fiscal year 2010
with the first shipment likely to commence in early Q2 of fiscal year
2010.
Omeprazole Mg is indicated for the treatment of heartburn. Dr. Reddy’s
formulation contains 20.6mg Omeprazole Mg and the dosage form is a
capsule.
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy’s
Established in 1984, Dr. Reddy’s Laboratories (NYSE:RDY) is an emerging
global pharmaceutical company whose purpose is providing affordable and
innovative medicines for healthier lives. Dr. Reddy’s is vertically
integrated with a presence across the pharmaceutical value chain through
its core businesses of Global Generics, Pharmaceutical Services & Active
Ingredients (PSAI), and Proprietary Products, which includes New
Chemical Entities, Generic Biopharmaceuticals and Differentiated
formulations. The company’s products are marketed globally, with a focus
on India, US, Europe and Russia. For more information please see: www.drreddys.com.
Investors and Financial Analysts:
Kedar
Upadhye, +91-40-66834297
kedaru@drreddys.com
Raghavender
R, +91-40-66511529
raghavenderr@drreddys.com
Milan
Kalawadia, +1-908-203-4931 (North America)
mkalawadia@drreddys.com
Media:
Mythili
M, +91-40-66511620
mythilim@drreddys.com
Rajan
S, +91-40-66511725
rajans@drreddys.com
